

## Alzheimer's disease drug market is declining and it is expected to fall till 2016

10 December 2013 | News | By BioSpectrum Bureau

### Alzheimer's disease drug market is declining and it is expected to fall till 2016



Bharat Book Bureau presents Alzheimer's pipeline drugs review, Alzheimer's disease drug market & forecast - global analysis. This report Alzheimer's disease drug market is on the curvature stage. Since 2003, there is not any single "magic bullet" launched in the market to prevent or cure it. However, all current marketed products are going to be generic in the next 3-4 years.

There are high unmet medical needs. The current unmet needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel therapies. If successful, they will be in a position to command premium prices and tap the existing opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer's disease drug market.

"Alzheimer's Pipeline Drugs Review, Alzheimer's Disease Drug Market & Forecast - Global Analysis" provides a comprehensive assessment of the fast-evolving, high-growth Global Alzheimer's Disease Market. This 110 page report with 29 Figures and 11 Tables studies the Global Alzheimer's Disease Drug Market.

From the year 2009 Alzheimer's disease drug market is declining and it is expected to fall till 2016. But with the expected launch of some Alzheimer's drugs from the year 2017 onwards, Alzheimer's disease drug market is expected to revive in the coming years.

However due to absence of exact potential drugs there will always remain a huge unmet Alzheimer's Drug Market. For the year 2018 Alzheimer's disease Drug Market will be just 10% of unmet Alzheimer's Disease Drug Market.